Stunning Changes in FDA's Software Regulation (+)
- Speaker:Casper Uldriks
- Date: 16th May 2019 10:00 AM PST | 01:00 PM EST
- Product Code:GRC-90610
Left to Register
Live Session - How it works
- Username and Password will be sent to you within 24 hours prior to the webinar.
- Presentation handouts in pdf format will be emailed to along with the login instructions or few hours before the meeting starts.
- Login to the session by clicking on “Join the Meeting” in the login instructions and then dial the number to connect to the meeting audio or use your Computer to connect to audio. Please use the name and the email address you used at the time of registration to join the meeting.
- Get answer to your queries through interactive Q&A sessions. The Q and A sessions are at the end of the meeting. The expert will complete his/ her presentation and then the phone lines will be open for the audience to discuss your questions.
- Please let us know your thoughts and views at the end of webinar, your valuable feedback will help us improve our Training programs.
- Certificate of attendance is emailed to you within 6 working days from the date the webinar was completed. If you don’t receive an email within 6 days. Please email our email@example.com
Recorded Session - How it works
- Login Information with Password to view the webinar will be emailed to you within 48 hours from the date the Live webinar was completed. The link to the recording is for a single person use only and it is valid for 6 months or the actual duration the recording was purchased.
- Please click on the link to access the Recording and type in the password provided in the email.
- Presentation and other handouts will be emailed to you in a pdf format.
Training CD - How it works
- Free shipment within 2 working days, from the date the webinar was completed. The presentation and other handouts will be emailed to you in a pdf format if we are unable to attach them in the CD or USB.
(For more information about our products contact +1- 248-233-2049)
If you are unable to attend the meeting Live then you can opt in for the Live Recording instead. Access the Recording of the Training for 6 months. Contact our support for any questions. To prepare an invoice to pay by Check or Wire email us at firstname.lastname@example.org.
This webinar will highlight the changing circumstances with respect to software regulations and FDA’s approach from a regulation to voluntary standard. How to understand the qualifications and terms of participation to clear its software for marketing, what to do in case of cybersecurity intrusion and how to update regulatory program as mobile apps are removed from FDA’s regulatory oversight.
Congress removed some software products out of FDA's jurisdiction. On balance, the benefit did not outweigh the cost of the regulatory burden. That is a stunning "least burdensome approach." FDA is planning to give additional regulatory relief to its regulation of software. Now the question is whether or not you are in a "relief zone." Those boundaries are grey. We are looking at no regulation of some software, easier regulation for some software premarket (510(k)) submissions and an accelerated assessment of products deemed part of a "Digital Health" initiative, which has a startling change for premarket access. Firms can clear their own Software 510(k).
Objectives of the Presentation
- Identify software that is no longer regulated by the FDA
- Identify FDA guidance documents that will be revised or withdrawn
- Identify mobile apps exempt from FDA regulation
- Identify premarket shortcuts for software 510(k) clearance
- Identify recall reporting options for cybersecurity problems
- Highlight the FDA's Digital Health initiative
Why Should you Attend:
FDA's regulation of software provides major relief to firms involved with software, especially low risk software. Firms should be re-evaluated the software they market to determine if the regulatory relief applies to the software they market. Are you developing your risk assessment? Criteria so you can justify saying, (1) "My software is not regulated" (2) "Does my firm meet the criteria to clear its own software 510(k)'s?" or (3) "My software qualifies as digital health software." These are questions that require work now so that you reap the rewards going forward.
- 21st century cure act impact
- Software no longer under FDA jurisdiction
- Changes in premarket requirements
- Voluntary controls short cuts
- Post market reporting options
- Digital Health Initiative - FDA clearance not required
Who will Benefit
- Regulatory affairs directors
- Software designers / specification developers
- Production managers
- Quality assurance directors
- In-house legal counsel
- Importers of software-based devices
- Software engineers
- information technology managers
- Third party software services
- Regulatory Affairs Managers
- Healthcare institution risk managers
- Complaint investigation teams
- Quality assurance directors
FDA has struggled with regulating software for about 25 years. When the Federal Food, Drug, and Cosmetic Act (FDCA) was amended in 1976 to regulate devices, software was not considered. It did not exist as a regulatory issue. With the advent of increasingly sophisticated software, the increasing use of software and the dramatic increase of mobile apps, FDA, the industry, and Congress became aware that FDA was in over its head. Congress has redefined the scope of FDA's jurisdiction over software. In a rare case in history, FDA is scaling back its regulatory boundaries.
Mr. Uldriks held a number of positions at FDA, such as an investigator in FDA's New England office, in the Office of the Commissioner in Legislative Affairs and in the Center for Devices and Radiological Health (CDRH), where he served as CDRH's Associate Director for Regulatory Guidance and Government Affairs. He helped to guide CDRH to develop and implement various medical device related amendments to the Food, Drug, and Cosmetic Act, regulations and guidance documents. For years he has trained FDA staff on medical law and has been a featured speaker at many professional conferences involving FDA's medical device program.
Bar Admissions: Massachusetts, 1986 and District of Columbia, 2011
Education: Suffolk University Law School, Boston, Massachusetts, 1986.